Stock Events

Stock Events

MEI Pharma 

€4.2
24
+€0+0% Tuesday 08:13

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 23
€1.61
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.39
-0.06
0.28
0.61
Expected EPS
N/A
Actual EPS
N/A

Financials

-135.78%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
36.38MRevenue
-49.39MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MMI0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
TG Therapeutics
TGTX
Mkt Cap5.35B
TG Therapeutics focuses on novel treatments for B-cell malignancies and autoimmune diseases, directly competing with MEI Pharma's cancer therapy developments.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation specializes in oncology products, including therapies for hematologic cancers, overlapping with MEI Pharma's research and development focus.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a major player in the development of treatments for cancer and other diseases, competing with MEI Pharma in the oncology sector.
Agios Pharmaceuticals
AGIO
Mkt Cap2.06B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, directly competing with MEI Pharma's approach to cancer treatment.
Karyopharm Therapeutics
KPTI
Mkt Cap132.78M
Karyopharm Therapeutics focuses on nuclear export inhibitors for cancer treatment, competing in the same therapeutic area as MEI Pharma.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad oncology portfolio, making it a competitor across various aspects of MEI Pharma's business.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a diverse range of cancer treatments, including therapies that directly compete with MEI Pharma's product pipeline.

About

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Show more...
CEO
Dr. Daniel P. Gold
Employees
102
Country
United States
ISIN
US55279B3015
WKN
000A3D69W

Listings

XNAS
US
LITS
LSE
GB
0JW9.LSE
BOATS
BOATS
LITS.BOATS

0 Comments

Share your thoughts

FAQ

What is MEI Pharma stock price today?▼
The current price of MMI0.F is €4.2 EUR — it has increased by +0% in the past 24 hours. Watch MEI Pharma stock price performance more closely on the chart.
What is MEI Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MEI Pharma stocks are traded under the ticker MMI0.F.
What is MEI Pharma revenue for the last year?▼
MEI Pharma revenue for the last year amounts to 36.38M EUR.
What is MEI Pharma net income for the last year?▼
MMI0.F net income for the last year is -49.39M EUR.
Does MEI Pharma pay dividends?▼
Yes, MMI0.F dividends are paid en. The last dividend per share was 1.61 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does MEI Pharma have?▼
As of April 07, 2026, the company has 102 employees.
In which sector is MEI Pharma located?▼
MEI Pharma operates in the Healthcare sector.
When did MEI Pharma complete a stock split?▼
MEI Pharma has not had any recent stock splits.
Where is MEI Pharma headquartered?▼
MEI Pharma is headquartered in San Diego, United States.